Eversense®, The World's First and Only Long-term CGM System Is Now Covered By Medicare

Check Your Patient's Eligibility

CGM Continues to Evolve

CGMs(Continuous Glucose Monitors) today need to be replaced every 7,10, or 14 days and can be complex and burdensome for some patients.

Technologies currently available on the market have issues that may impact acceptance, including:

  • Short sensor life
  • Accuracy limitations
  • Issues with sensor self-insertion and removal
  • Issues with skin irritations caused by adhesives 

The Eversense® Difference

The Eversense® CGM system balances performance, safety and patient experience with a professionally implanted sensor that lasts up to 90 days.

It was designed for simplicity and continuous feedback, so it's a great fit for patients who are striving for better self-management and desire low complexity.

Imagine an Easier, More Reliable Way For Your Patients to Manage Diabetes With:

A professionally inserted sensor that fits comfortably under your patient's skin and lasts for up to 90 days

Removable and re-attachable transmitter provides flexibility without wasting a sensor

On-body vibrations that alert your patient when glucose levels are either too high or too low

An easy way for your patients to automatically share important data with you

Helps to Overcome Challenges that Patients May Experience Including:3

 
  • Dexterity
  • Complexity
  • Memory
  • Audio and visual challenges

Key Benefits of the Eversense® System, Include:

 
  • Adherence–improved with easy to remove and reapply transmitter
  • Exceptional accuracy with a MARD of 8.5%1
  • Clinically proven to help lower A1c2
  • On-body vibratory patient alerts1,3
  • Data can be shared with Health Care Provider, friends and family
  • Under-the-skin sensor helps patients reach unprecedented levels of wear time (90 days)2
  • Sensor is protected in a subcutaneous pocket eliminating accidental dislodging
  • Fewer insertions–4 versus up to 26-52 per year
 

4 Simple Questions to Determine Medicare Eligibility4

Therapeutic CGMs are considered reasonable and necessary by Medicare when all following coverage criteria are met:

  1. The beneficiary has diabetes mellitus; and,
  2. The beneficiary is insulin-treated with multiple (three or more) daily administrations of insulin or a Medicare-covered continuous subcutaneous insulin infusion (CSII) pump; and,
  3. The beneficiary's insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of blood glucose monitor (BGM) or CGM testing results (note: some regional Medicare Administrative Contractors may require documentation of 4 or more fingerstick blood glucose checks daily); and,
  4. Within six (6) months prior to ordering the CGM, the treating practitioner has an in person visit with the beneficiary to evaluate their diabetes control and determined that criteria (1-3) above are met4 (note: some regional Medicare Administrative Contractors may require every 6-month visits); and, routine recommended follow-up care is expected.

Learn More about Ordering and Reimbursement

Contact Us

The Eversense CGM system can make a significant difference in your Medicare patients' lives. For more information on Medicare coverage for your patients, please contact your sales representative or click on this link. It will be our pleasure to answer any questions you may have about Eversense.

Contact Us
  1. Eversense CGM System Summary of Safety and Effectiveness Data (SSED) #P160048.
  2. Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.
  3. Engler R, Routh TL, Lucisano JY. Adoption Barriers for Continuous Glucose Monitoring and Their Potential Reduction With a Fully Implanted System: Results From Patient Preference Surveys. Clinical Diabetes. 2018;36(1):50-58. doi:10.2337/cd17-0053.
  4. Centers for Medicare & Medicaid Services : Medicare Coverage Database(MCD) (2020 October 17) Retrieved March 24, 2021, From https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38659

Disclaimer

The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a Health Care Provider. The Eversense CGM System is a prescription device; patients should talk to their Health Care Provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.

Eversense, Eversense Continuous Glucose Monitoring, Eversense CGM, Eversense Sensor, Eversense Smart Transmitter, Eversense App and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.
Other brands and their products are trademarks or registered trademarks of their respective holders.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System.
Android is a trademark of Google LLC.

© 2021 Senseonics, Incorporated. All rights reserved.
© 2021 Ascensia Diabetes Care Holdings AG. All rights reserved.